cilostazol has been researched along with Dyslipidemia in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication." | 6.47 | Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? ( Corrado, E; Mikhailidis, DP; Patti, AM; Rini, GB; Rizzo, M, 2011) |
| "Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication." | 2.47 | Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? ( Corrado, E; Mikhailidis, DP; Patti, AM; Rini, GB; Rizzo, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rizzo, M | 1 |
| Corrado, E | 1 |
| Patti, AM | 1 |
| Rini, GB | 1 |
| Mikhailidis, DP | 1 |
| Shinohara, Y | 1 |
| Liao, JK | 1 |
| Falconer, TM | 1 |
| Eikelboom, JW | 1 |
| Hankey, GJ | 1 |
| Norman, PE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for cilostazol and Dyslipidemia
| Article | Year |
|---|---|
Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?
Topics: Atherosclerosis; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Diabetes Mellitus, Type 2 | 2011 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; H | 2010 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Management of peripheral arterial disease in the elderly: focus on cilostazol.
Topics: Aged; Cilostazol; Diabetic Angiopathies; Dose-Response Relationship, Drug; Dyslipidemias; Humans; Hy | 2008 |